01:17 , Mar 13, 2019 |  BC Extra  |  Company News

FDA approves Aerie glaucoma therapy Rocklatan

Aerie said late Tuesday FDA approved Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is a fixed-dose combination of Aerie's Rhopressa netarsudil 0.02%, a dual inhibitor of...
00:04 , Oct 12, 2018 |  BC Innovations  |  Emerging Company Profile

Spinogenix’s Spine Craft

Spinogenix Inc. is developing small molecules for cognitive impairment in neurodegenerative diseases that rebuilds dendritic spines to reverse, not just halt, synaptic loss. CNS synapses that relay signals involved in memory and cognitive function are...
17:39 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting Rho kinase could help to treat AD. In primary rat cortical neurons stimulated with DKK1 to produce β amyloid, the Rho kinase inhibitor Eril...
22:56 , Aug 9, 2018 |  BC Extra  |  Preclinical News

New biological insight could lead to obesity treatment

By identifying a mechanism in dietary fat uptake, researchers from Yale University School of Medicine suggest a compound marketed for glaucoma could have therapeutic applications in obesity. The study was published Thursday in Science. Dietary...
18:18 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Aerie's Roclatan under FDA review with March PDUFA

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) said FDA accepted for review an NDA for Roclatan netarsudil/latanoprost to reduce intraocular pressure (IOP) in glaucoma or ocular hypertension. The PDUFA date is March 14, 2019. Roclatan met its primary...
18:41 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA approves Aerie's Rhopressa to lower IOP

FDA approved Rhopressa netarsudil 0.02% from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company plans to launch the drug in 2Q18. The approval...
21:38 , Dec 19, 2017 |  BC Extra  |  Company News

FDA approves Aerie's Rhopressa

FDA approved Rhopressa netarsudil 0.02% from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company plans to launch the drug in 2Q18. The approval...
00:32 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Aerie's Rhopressa wins FDA panel votes

An FDA advisory committee voted 9-1 on Oct. 13 that the efficacy of Rhopressa netarsudil 0.02% (AR-13324) from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shown in clinical trials outweighs the candidate's safety risks. The panel also voted...
21:41 , Oct 13, 2017 |  BC Extra  |  Company News

Aerie's Rhopressa wins FDA panel votes

An FDA advisory committee voted 9-1 on Friday that the efficacy of Rhopressa netarsudil 0.02% from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shown in clinical trials outweighs the candidate's safety risks. The panel also voted 10-0 that...
22:30 , Oct 11, 2017 |  BC Extra  |  Company News

FDA reviewers concur with Aerie on Rhopressa's efficacy

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $8.95 (16%) to $64.30 on Wednesday after FDA released briefing documents ahead of an advisory committee meeting to discuss an NDA for Rhopressa netarsudil 0.02%. Reviewers said they concurred with...